Pre-made Etaracizumab benchmark antibody ( Whole mAb, anti-ITGAV_ITGB3 therapeutic antibody, Anti-CD51/MSK8/VNRA/VTNR;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Etaracizumab benchmark antibody (Whole mAb, anti-ITGAV_ITGB3 therapeutic antibody, Anti-CD51/MSK8/VNRA/VTNR;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Etaracizumab, also known as etaratuzumab,[citation needed] MEDI-522, trade name Abegrin, is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer, ovarian cancer and various other types of cancer. It is manufactured by MedImmune.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-195-1mg	1mg	3090
GMP-Bios-ab-195-10mg	10mg	Inquiry
GMP-Bios-ab-195-100mg	100mg	Inquiry
GMP-Bios-ab-195-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Etaracizumab biosimilar, Whole mAb, Anti-ITGAV;ITGB3 Antibody: Anti-CD51/MSK8/VNRA/VTNR;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 therapeutic antibody
INN Name	Etaracizumab
Target	ITGAV_ITGB3
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2008
Year Recommended	2009
Companies	Applied Molecular Evolution;MedImmune
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Colorectal cancer;Malignant melanoma;Prostate cancer;Psoriasis;Rheumatoid arthritis
Development Tech	na